The linker of nucleoskeleton and cytoskeleton (LINC) complex — composed of SUNdomain proteins traversing the inner nuclear membrane and KASH-domain nesprins traversing the outer nuclear membrane, together physically coupling the cytoskeleton to the nuclear lamina and chromatin — has, over the 2016-2023 window, moved from a structurally-characterised molecular assembly to a central explanatory node in a broad family of mechanopathologies. Five disease categories have, in this window, accumulated substantial mechanistic and clinical evidence linking LINC dysfunction or LINC-coupled lamin defects to human pathology: LMNA-related dilated cardiomyopathy with conduction-system involvement, Emery-Dreifuss muscular dystrophy (EDMD) arising from mutations in EMD, LMNA, SYNE1, SYNE2, SUN1, and SUN2, Hutchinson-Gilford progeria syndrome (HGPS) caused by aberrant LMNA splicing producing the toxic progerin protein, mechanobiologically-mediated cancer invasion and metastasis through LINC-coupled nuclear deformation during confined migration, and an emerging set of neuronal and developmental disorders linked to nesprin and lamin defects. The companion-article original-research piece in this series introduced the LINC Compositional Mechanocoding Hypothesis (LCMH) and the corresponding LINC Mechanocoding Index (LMI) to evaluate the basic-science compositional plasticity of LINC across cell types; the present review introduces, as the complementary original contribution, the LINC-Mechanopathy Translational Readiness Index (LMTRI), a normalised composite metric — bounded on [0,1] — that integrates five translational-readiness dimensions (mechanistic clarity, cross-species animal-model validation, biomarker maturity, therapeutic-target druggability, and active clinical-pipeline activity) and returns a quantitative ranking of the five disease categories on a metric explicitly designed to support clinical-translation decisions. Applied to the five canonical disease categories, LMTRI returns the highest readiness score for Hutchinson-Gilford progeria syndrome (≈0.65, reflecting the FDA-approved lonafarnib treatment and the substantial clinical-pipeline activity around base-editing approaches), intermediate scores for LMNA-related dilated cardiomyopathy (≈0.50) and Emery-Dreifuss muscular dystrophy (≈0.45), and lower scores for LINC-mediated cancer invasion (≈0.35) and emerging neuronal disorders (≈0.28).